Agnieszka Dansonka-Mieszkowska

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3584314/publications.pdf

Version: 2024-02-01

52 papers

3,657 citations

201674 27 h-index 52 g-index

52 all docs 52 docs citations

times ranked

52

7051 citing authors

#	Article	IF	Citations
1	Unique gastrointestinal stromal tumor with PDGFRA D842Y mutationâ€"evaluation of in vivo sensitivity to imatinib. Memo - Magazine of European Medical Oncology, 2021, 14, 208-213.	0.5	1
2	The utility of fluorescence in situ hybridization (FISH) in determining DNA damage-inducible transcript 3 (DDIT3) amplification in dedifferentiated liposarcomas – an important diagnostic pitfall. Pathology Research and Practice, 2021, 225, 153555.	2.3	4
3	Clinical importance of <i>FANCD2, BRIP1, BRCA1, BRCA2</i> and <i>FANCF</i> expression in ovarian carcinomas. Cancer Biology and Therapy, 2019, 20, 843-854.	3.4	20
4	Adult height is associated with increased risk of ovarian cancer: a Mendelian randomisation study. British Journal of Cancer, 2018, 118, 1123-1129.	6.4	15
5	Assessment of moderate coffee consumption and risk of epithelial ovarian cancer: a Mendelian randomization study. International Journal of Epidemiology, 2018, 47, 450-459.	1.9	15
6	Variants in genes encoding small GTPases and association with epithelial ovarian cancer susceptibility. PLoS ONE, 2018, 13, e0197561.	2.5	9
7	Clinical importance of the EMSY gene expression and polymorphisms in ovarian cancer. Oncotarget, 2018, 9, 17735-17755.	1.8	4
8	Enrichment of putative PAX8 target genes at serous epithelial ovarian cancer susceptibility loci. British Journal of Cancer, 2017, 116, 524-535.	6.4	23
9	Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. Nature Genetics, 2017, 49, 680-691.	21.4	356
10	No Evidence That Genetic Variation in the Myeloid-Derived Suppressor Cell Pathway Influences Ovarian Cancer Survival. Cancer Epidemiology Biomarkers and Prevention, 2017, 26, 420-424.	2.5	3
11	Adult body mass index and risk of ovarian cancer by subtype: a Mendelian randomization study. International Journal of Epidemiology, 2016, 45, 884-895.	1.9	71
12			
12	Unsupervised analysis reveals two molecular subgroups of serous ovarian cancer with distinct gene expression profiles and survival. Journal of Cancer Research and Clinical Oncology, 2016, 142, 1239-1252.	2.5	30
13	expression profiles and survival. Journal of Cancer Research and Clinical Oncology, 2016, 142,	2.5 3.8	30
	expression profiles and survival. Journal of Cancer Research and Clinical Oncology, 2016, 142, 1239-1252. Assessing the genetic architecture of epithelial ovarian cancer histological subtypes. Human Genetics,		
13	expression profiles and survival. Journal of Cancer Research and Clinical Oncology, 2016, 142, 1239-1252. Assessing the genetic architecture of epithelial ovarian cancer histological subtypes. Human Genetics, 2016, 135, 741-756. Association of vitamin D levels and risk of ovarian cancer: a Mendelian randomization study.	3.8	19
13	expression profiles and survival. Journal of Cancer Research and Clinical Oncology, 2016, 142, 1239-1252. Assessing the genetic architecture of epithelial ovarian cancer histological subtypes. Human Genetics, 2016, 135, 741-756. Association of vitamin D levels and risk of ovarian cancer: a Mendelian randomization study. International Journal of Epidemiology, 2016, 45, 1619-1630. Genome-Wide Meta-Analyses of Breast, Ovarian, and Prostate Cancer Association Studies Identify Multiple New Susceptibility Loci Shared by at Least Two Cancer Types. Cancer Discovery, 2016, 6,	3.8	19
13 14 15	expression profiles and survival. Journal of Cancer Research and Clinical Oncology, 2016, 142, 1239-1252. Assessing the genetic architecture of epithelial ovarian cancer histological subtypes. Human Genetics, 2016, 135, 741-756. Association of vitamin D levels and risk of ovarian cancer: a Mendelian randomization study. International Journal of Epidemiology, 2016, 45, 1619-1630. Genome-Wide Meta-Analyses of Breast, Ovarian, and Prostate Cancer Association Studies Identify Multiple New Susceptibility Loci Shared by at Least Two Cancer Types. Cancer Discovery, 2016, 6, 1052-1067. Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast–ovarian cancer	3.8 1.9 9.4	19 111 157

#	Article	IF	CITATIONS
19	Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with risk of clear cell ovarian cancer. Oncotarget, 2016, 7, 69097-69110.	1.8	5
20	Inherited variants affecting RNA editing may contribute to ovarian cancer susceptibility: results from a large-scale collaboration. Oncotarget, 2016, 7, 72381-72394.	1.8	13
21	The significance of c.690G>T polymorphism (rs34529039) and expression of the <i>CEBPA</i> gene in ovarian cancer outcome. Oncotarget, 2016, 7, 67412-67424.	1.8	17
22	Epithelialâ€Mesenchymal Transition (EMT) Gene Variants and Epithelial Ovarian Cancer (EOC) Risk. Genetic Epidemiology, 2015, 39, 689-697.	1.3	22
23	The Novel Gene CRNDE Encodes a Nuclear Peptide (CRNDEP) Which Is Overexpressed in Highly Proliferating Tissues. PLoS ONE, 2015, 10, e0127475.	2.5	40
24	Common Genetic Variation In Cellular Transport Genes and Epithelial Ovarian Cancer (EOC) Risk. PLoS ONE, 2015, 10, e0128106.	2.5	44
25	The putative oncogene, <i>CRNDE, </i> is a negative prognostic factor in ovarian cancer patients. Oncotarget, 2015, 6, 43897-43910.	1.8	51
26	Cell-type-specific enrichment of risk-associated regulatory elements at ovarian cancer susceptibility loci. Human Molecular Genetics, 2015, 24, 3595-3607.	2.9	40
27	Identification of six new susceptibility loci for invasive epithelial ovarian cancer. Nature Genetics, 2015, 47, 164-171.	21.4	221
28	Network-Based Integration of GWAS and Gene Expression Identifies a <i>HOX</i> -Centric Network Associated with Serous Ovarian Cancer Risk. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 1574-1584.	2.5	28
29	Genome-wide Analysis Identifies Novel Loci Associated with Ovarian Cancer Outcomes: Findings from the Ovarian Cancer Association Consortium. Clinical Cancer Research, 2015, 21, 5264-5276.	7.0	33
30	Evaluating the ovarian cancer gonadotropin hypothesis: A candidate gene study. Gynecologic Oncology, 2015, 136, 542-548.	1.4	15
31	Germline SMARCA4 mutations in patients with ovarian small cell carcinoma of hypercalcemic type. Orphanet Journal of Rare Diseases, 2015, 10, 32.	2.7	31
32	Cis-eQTL analysis and functional validation of candidate susceptibility genes for high-grade serous ovarian cancer. Nature Communications, 2015, 6, 8234.	12.8	63
33	Shared genetics underlying epidemiological association between endometriosis and ovarian cancer. Human Molecular Genetics, 2015, 24, 5955-5964.	2.9	68
34	Common Genetic Variation in Circadian Rhythm Genes and Risk of Epithelial Ovarian Cancer (EOC). Journal of Genetics and Genome Research, 2015, 2, .	0.3	25
35	Variation in NF-κB Signaling Pathways and Survival in Invasive Epithelial Ovarian Cancer. Cancer Epidemiology Biomarkers and Prevention, 2014, 23, 1421-1427.	2.5	13
36	Risk of Ovarian Cancer and the NF-κB Pathway: Genetic Association with <i>IL1A</i> and <i>TNFSF10</i> Cancer Research, 2014, 74, 852-861.	0.9	48

#	Article	IF	Citations
37	Large-Scale Evaluation of Common Variation in Regulatory T Cell–Related Genes and Ovarian Cancer Outcome. Cancer Immunology Research, 2014, 2, 332-340.	3.4	21
38	Genome-wide association study of subtype-specific epithelial ovarian cancer risk alleles using pooled DNA. Human Genetics, 2014, 133, 481-497.	3.8	23
39	Consortium analysis of gene and gene–folate interactions in purine and pyrimidine metabolism pathways with ovarian carcinoma risk. Molecular Nutrition and Food Research, 2014, 58, 2023-2035.	3.3	16
40	GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer. Nature Genetics, 2013, 45, 362-370.	21.4	326
41	Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nature Genetics, 2013, 45, 371-384.	21.4	493
42	Epigenetic analysis leads to identification of HNF1B as a subtype-specific susceptibility gene for ovarian cancer. Nature Communications, 2013, 4, 1628.	12.8	144
43	Analysis of Over 10,000 Cases Finds No Association between Previously Reported Candidate Polymorphisms and Ovarian Cancer Outcome. Cancer Epidemiology Biomarkers and Prevention, 2013, 22, 987-992.	2.5	20
44	Identification and molecular characterization of a new ovarian cancer susceptibility locus at $17q21.31$. Nature Communications, 2013 , 4 , 1627 .	12.8	98
45	p19 ^{INK4d} mRNA and protein expression as new prognostic factors in ovarian cancer patients. Cancer Biology and Therapy, 2013, 14, 973-981.	3.4	11
46	Ovarian small cell carcinoma of hypercalcemic type – evidence of germline origin and smarca4 gene inactivation. a pilot study. Polish Journal of Pathology, 2013, 4, 238-246.	0.3	85
47	A novel germline PALB2 deletion in Polish breast and ovarian cancer patients. BMC Medical Genetics, 2010, 11, 20.	2.1	96
48	PIK3CA amplification associates with resistance to chemotherapy in ovarian cancer patients. Cancer Biology and Therapy, 2009, 8, 21-26.	3.4	81
49	Loss of heterozygosity on chromosome 22q in gastrointestinal stromal tumors (GISTs): a study on 50 cases. Laboratory Investigation, 2005, 85, 237-247.	3.7	34
50	A great majority of GISTs with PDGFRA mutations represent gastric tumors of low or no malignant potential. Laboratory Investigation, 2004, 84, 874-883.	3.7	292
51	Evaluation of NF2 and NF1 Tumor Suppressor Genes in Distinctive Gastrointestinal Nerve Sheath Tumors Traditionally Diagnosed as Benign Schwannomas: A Study of 20 Cases. Laboratory Investigation, 2003, 83, 1361-1371.	3.7	65
52	Gastrointestinal Stromal Tumors with Internal Tandem Duplications in 3' End of KIT Juxtamembrane Domain Occur Predominantly in Stomach and Generally Seem to Have a Favorable Course. Modern Pathology, 2003, 16, 1257-1264.	5. 5	104